In 4 years, the rate of women receiving breast MRI nearly tripled, but it is underused in women most at risk for breast cancer and overused in women at average risk.
Accelerated approval of Perjeta (pertuzumab) was granted by the FDA as part of a complete treatment regimen for patients with early stage breast cancer before surgery.
Breast density laws ensure that women receive critical breast-health information, supporters say, but many of the laws broadly classify breast density and fail to account for varying levels of risk.
The use of 40 Gy in 15 fractions over 3 weeks is as effective and causes less damage to nearby tissue than a higher total dose of radiotherapy for breast cancer.
Researchers suggest that recommendations for the universal screening of breast cancer with mammography be reassessed.
Metabolic syndrome is more likely to develop in postmenopausal survivors of breast cancer than in postmenopausal women who never had the disease.
A review of new publications by the Update Committee for the American Society of Clinical Oncology found that the guidelines for the follow-up and management of patients with breast cancer who have completed treatment are still sound.
Women with primary breast cancer diagnosed at an advanced stage are at increased risk for the development of contralateral breast cancer (CBC), according to the results of a population-based study conducted in Sweden.
The FDA has approved a new ultrasound device to detect breast cancer in women with dense breasts. It will be used in conjunction with standard mammography in asymptomatic women with a negative mammogram.
In patients with heavily pretreated HER2-positive metastatic breast cancer, combination treatment with lapatinib and trastuzumab was associated with a median survival benefit of 4.5 months, according to the final results of a phase III study.